Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009)

被引：43

作者：

Mendes, Rodrigo E. ^{[1
]}

Farrell, David J. ^{[1
]}

Sader, Helio S. ^{[1
]}

Jones, Ronald N. ^{[1
,2
]}

机构：

[1] JMI Labs, N Liberty, IA 52317 USA

[2] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2010年 / 68卷 / 03期

关键词：

Tigecycline; Acinetobacter spp; Multidrug resistance; Nosocomial infections; EXPERIENCE; BAUMANNII;

D O I：

10.1016/j.diagmicrobio.2010.07.003

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

A total of 5127 Acinetobacter spp. were collected from 140 hospitals in 32 countries in North America (17.1%), Europe (22.9%), Latin America (25.2%), and the Asia-Pacific (APAC) region (34.8%). Tigecycline MIC distributions were bimodal against isolates from North America and APAC region, while a unimodal pattern was noted for strains from Latin America. A variable MIC distribution was noted in Europe. Only tigecycline (MIC50/90, 0.5/2 mu g/mL) and polymyxin B (MIC50/90, 0.5/1 mu g/mL; 98.6% susceptible) exhibited high activity against Acinetobacter spp. Overall, tigecycline inhibited at least 90.0% of Acinetobacter spp. isolates from all countries evaluated at <= 2 mu g/mL, as well as 95.0% of those displaying multidrug resistance. Other tested agents showed limited activity and a significant (P < 0.001) trend toward decreased susceptibility during the study period. (C) 2010 Elsevier Inc. All rights reserved.

引用

页码：307 / 311

页数：5

共 19 条

[1] Clinical and Economic Consequences of Ventilator-Associated Pneumonia [J].